Johnson & Johnson (JNJ) said Tuesday that the latest results from a trial of the investigational nipocalimab plus standard of care administered to adults with generalized myasthenia gravis showed "maintained improvements" over 84 weeks.
The company said results from the additional analyses of its phase 3 study and the ongoing open-label extension evaluating the long-term efficacy and safety of nipocalimab produced "sustained reductions" in total immunoglobulin G.
Up to 128 weeks and 180 patient-years of follow-up in the open-label extensions "confirm a safety profile consistent" with its phase 3 study, Johnson & Johnson said.
The nipocalimab plus standard of care group showed four times greater odds of improving and maintaining the strength and function of different muscle groups, compared with placebo plus standard of care in the 24-week double-blind phase of the study.
Myasthenia gravis is a disease in which the immune system mistakenly makes antibodies, potentially blocking or disrupting normal signaling from nerves to muscles.
The company's shares were up 2.8% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。